Searched for
GLOBAL PHARMA OUTSOURCING
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- 30 Nifty stocks wipe out Rs 22.64 lakh crore investor wealth in 2026 so far; HDFC Bank, TCS lead routThirty Nifty 50 stocks have wiped out Rs 22.64 lakh crore in investor wealth this year. HDFC Bank and TCS led the decline, losing Rs 3.55 l...
- Nifty stuck in a range but small and midcaps are where real money is being made: Ashish ChaturmohtaIndian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- “Reallocate, Diversify, Reposition”: Ajay Srivastava flags rising macro risks for investorsIndian markets face rising macro risks from global shocks, currency pressure, and energy prices, impacting domestic consumption and corpora...
- Govt has eased FDI norms for foreign cos having small Chinese/Hong Kong stake: An explainerIndia has eased Foreign Direct Investment rules for companies with up to ten percent Chinese or Hong Kong shareholding. These firms can now...
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%If you are putting fresh money into the market, it might be a good idea to stay with companies that don't have much to do with global suppl...
- Healthcare, pharma sector to create 2-2.5 million new jobs by 2030: ReportThe country's healthcare and pharmaceutical sector is moving into a capability-led growth phase, with hiring increasingly focused on specia...
- 360 ONE Asset acquires stake in OneSource Specialty Pharma360 ONE Asset has acquired a stake in OneSource Specialty Pharma, a Contract Development and Manufacturing Organization (CDMO), for an undi...
- Outsourcing from US to Indian pharma cos likely to be affectedWith Barack Obama's election as the President of the United States, outsourcing of activities from the US to the Indian pharma industry mig...
- Accenture to expand lifesciences R&D unitWith global pharma companies waking up to technology outsourcing services as a tool to reduce the time to market of their R&D harvest.
- CRAMS cos buck pharma trend, give good returnsThe pharma sector may have underperformed the Sensex , but companies providing contract research and manufacturing services (CRAMS) to glob...
- PEs take fancy to pharma cos with outsourcing dealsSmall and mid-size pharma companies focused on outsourcing seem to have caught the attention of investors, if the recent investments by pri...
- DRL on prowl overseas to scale up R&D optionsIndia’s largest drug maker, Dr Reddy’s Laboratories, is on the prowl for overseas acquisitions to scale up its custom pharmaceutical servic...
- Global pharma cos to outsource in IndiaClinical Research outsourcing (CRO) is a young industry worth about 118 million dollars a year in India, but it is growing fast.
- Now, BPOs moves towards researchAfter BPOs & KPOs, outsourcing segments are all set to move towards Research Process Outsourcing (RPO).
Load More
